STOCKHOLM, Feb. 24, 2022 /PRNewswire/ -- The demand for Elekta's solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta's strongest order backlog ever. However, the global supply chain challenges remained, and revenue and margins came in lower than last year. We are fully committed to returning to revenue growth and margin expansion.
Gustaf Salford
President and CEO
Third quarter
First nine months
Significant events after the quarter
Group summary |
||||||||||
Q3 |
First nine months |
|||||||||
SEK M |
2021/22 |
2020/21 |
Δ |
2021/22 |
2020/21 |
Δ |
||||
Gross order intake |
4,441 |
3,954 |
8%4 |
12,467 |
12,032 |
5%4 |
||||
Net sales |
3,602 |
3,581 |
-3%4 |
10,309 |
10,096 |
4%4 |
||||
Gross margin |
36.7% |
38.7% |
-2 ppts |
37.5% |
41.6% |
-4,1 ppts |
||||
EBIT 1 |
340 |
468 |
-27% |
1,074 |
1,361 |
-21% |
||||
EBIT margin |
9.4% |
13.1% |
-3,6 ppts |
10.4% |
13.5% |
-3,1 ppts |
||||
Cash flow 2 |
187 |
496 |
-62% |
-173 |
886 |
-120% |
||||
Earnings per share, SEK 3 |
0.60 |
0.84 |
-29% |
1.93 |
2.39 |
-19% |
||||
1Including the contribution to Elekta Foundation of SEK 35 M reported in Q3 2021/22. |
||||||||||
2After continuous investments. |
||||||||||
3Before/after dilution. |
||||||||||
4Based on constant currency. |
For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Tobias Hägglöv, CFO
Tel: +46 76 107 47 99, e-mail: tobias.hagglov@elekta.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on February 24, 2022. (REGMAR)
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/elekta/r/interim-report--may-january-2021-22,c3513327
The following files are available for download:
Elekta Q3 Report 21_22 |
|
https://news.cision.com/elekta/i/group-summary-q3-2021-22,c3016428 |
Group summary Q3 2021-22 |